Application No.: 10/588,754 Docket No.: 5999-0525PUS3

Art Unit 1626

Reply to Non-Final Office Action

## AMENDMENTS TO THE SPECIFICATION

Please delete the text on page 22 of the specification at line 12-20 as follows:

<sub>6</sub>alkyl(SO<sub>2</sub>)R<sup>5</sup>, C<sub>0 6</sub>alkyl(SO)R<sup>5</sup>, OC<sub>2 6</sub>alkyl(SO)R<sup>5</sup> and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S;

R<sup>5</sup> and R<sup>6</sup> are independently selected from, H, C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl and aryl;

m is selected from 0, 1, 2, 3 or 4; n is selected from 0, 1, 2, 3 or 4; p is selected from 0, 1, 2, 3 or 4; and a salt or hydrate thereof.

Please delete the text on page 22 of the specification at lines 28-31 as follows:

In still a further aspect of the invention there is provided the compound of formula I for use in therapy, especially for the treatment of mGluR5 receptor mediated disorders, and for the treatment of neurological disorders, psychiatric disorders, gastrointestinal disorders and pain disorders.

2 of 19 ETP/GMD